A European forum for advancing precision cancer care through molecular tumour boards
We are pleased to invite you to the Molecular Tumour Board (MTB) Summit 2026, a European event dedicated to strengthening molecular tumour boards (MTBs) as a core pillar of high-quality precision oncology. Building on the Inaugural EUnetCCC Educational Seminar, the summit will bring together professionals from across the cancer care ecosystem to address how MTBs can help translate scientific advances into timely, effective, and more equitable patient care across Europe.
Why this summit matters
Precision oncology already offers a proven path to better treatment outcomes, fewer side effects, and effective use of healthcare resources, yet access remains highly unequal within and across European countries. The Molecular Tumour Board (MTB) Summit responds to that challenge by creating a focused space for clinical, scientific, technical, patient, and policy communities to address the practical conditions needed to make MTB-based precision cancer care more accessible, harmonised, and sustainable.
The meeting is designed as a focused 1.5-day in-person forum where participants can examine not only how MTBs work inside individual institutions, but also how they can be strengthened across regions, countries, and European initiatives. In doing so, this summit aims to move from foundational learning to implementation, collaboration, and system-level improvement across cancer centres and networks.
Practical details
- Date: 24-25 September 2026
- Venue: IFO Regina Elena, Rome, Italy
- Format: On-site, maximum capacity of 200 participants
- Registration fee: Free of charge
- Travel & accommodation: Participants are responsible for their own travel and accommodation expenses
Target audience: Oncologists, pathologists, molecular biologists, bioinformaticians, translational researchers, clinical trial specialists, hospital leaders, patient representatives, policy makers, regulators, payers, and relevant industry stakeholders.
What will the summit address?
- How can we organise effective and sustainable MTB models in different healthcare settings and what are the strategies to expand access across borders and healthcare systems?
- How can we strengthen collaboration across centres, networks, and European initiatives to reduce fragmentation and support implementation at scale?
- How can we improve patient pathways from MTB recommendation to treatment access, clinical trial enrolment, and how can we incorporate patient perspectives into this?
- How can we support workforce development and strengthen institutional capacity and tie this to CCC certification?
- How can we use MTBs as engines for translational research and as platforms for real world evidence generation to support health technology assessment and reimbursement pathways?
Programme highlights
- Plenary sessions on MTB organisation, health care policy and equity, patient perspectives and ethics, access to clinical trials, implementation of in-house diagnostic solutions, clinical decision support systems, and health technology assessment and reimbursement pathways.
- Parallel sessions on inputs to CCC certification standards and capacity building, and translational research integration into MTB workflows.
A European forum for advancing precision cancer care through molecular tumour boards
We are pleased to invite you to the Molecular Tumour Board (MTB) Summit 2026, a European event dedicated to strengthening molecular tumour boards (MTBs) as a core pillar of high-quality precision oncology. Building on the Inaugural EUnetCCC Educational Seminar, the summit will bring together professionals from across the cancer care ecosystem to address how MTBs can help translate scientific advances into timely, effective, and more equitable patient care across Europe.
Why this summit matters
Precision oncology already offers a proven path to better treatment outcomes, fewer side effects, and effective use of healthcare resources, yet access remains highly unequal within and across European countries. The Molecular Tumour Board (MTB) Summit responds to that challenge by creating a focused space for clinical, scientific, technical, patient, and policy communities to address the practical conditions needed to make MTB-based precision cancer care more accessible, harmonised, and sustainable.
The meeting is designed as a focused 1.5-day in-person forum where participants can examine not only how MTBs work inside individual institutions, but also how they can be strengthened across regions, countries, and European initiatives. In doing so, this summit aims to move from foundational learning to implementation, collaboration, and system-level improvement across cancer centres and networks.
Practical details
- Date: 24-25 September 2026
- Venue: IFO Regina Elena, Rome, Italy
- Format: On-site, maximum capacity of 200 participants
- Registration fee: Free of charge
- Travel & accommodation: Participants are responsible for their own travel and accommodation expenses
Target audience: Oncologists, pathologists, molecular biologists, bioinformaticians, translational researchers, clinical trial specialists, hospital leaders, patient representatives, policy makers, regulators, payers, and relevant industry stakeholders.
What will the summit address?
- How can we organise effective and sustainable MTB models in different healthcare settings and what are the strategies to expand access across borders and healthcare systems?
- How can we strengthen collaboration across centres, networks, and European initiatives to reduce fragmentation and support implementation at scale?
- How can we improve patient pathways from MTB recommendation to treatment access, clinical trial enrolment, and how can we incorporate patient perspectives into this?
- How can we support workforce development and strengthen institutional capacity and tie this to CCC certification?
- How can we use MTBs as engines for translational research and as platforms for real world evidence generation to support health technology assessment and reimbursement pathways?
Programme highlights
- Plenary sessions on MTB organisation, health care policy and equity, patient perspectives and ethics, access to clinical trials, implementation of in-house diagnostic solutions, clinical decision support systems, and health technology assessment and reimbursement pathways.
- Parallel sessions on inputs to CCC certification standards and capacity building, and translational research integration into MTB workflows.